Review



htb 15 j cells  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    ATCC htb 15 j cells
    Depletion of VAMP8 impairs STAT1 phosphorylation downstream of IFN-I signaling but does not alter WNV replication. (A and B) wt A549 cells were treated with nontargeting control (control) or VAMP8-targeting (VAMP8) siRNAs for 24 h, followed by infection with WNV 385-99 (MOI of 0.1) for 72 h. Supernatants and lysates of infected cells were collected at 1, 6, 24, 48, and 72 h p.i. to assess viral loads by plaque assays (A) and protein expression and phosphorylation by Western blotting (B). (C and D) The bands in the Western blot were quantified by densitometry as described in the legend of Fig. 1. (E to J) wt A549 (E to I) or ATCC HTB-15 (J) cells were treated with nontargeting control (siControl) or VAMP8-targeting (siVAMP8) siRNAs for 24 h, followed by treatment with recombinant human IFN-β-1a (500 U/ml) (E, F, I, and J) or human IFN-γ (500 U/ml) (G and H). IFN treatments shown in panels E, F, I, and J were done for 16 h. Cells were lysed, and either protein (E to H) or RNA (I and J) was isolated for analysis by Western blotting or qRT-PCR, respectively. Error bars represent standard deviations. Gene expression data were analyzed using one-way ANOVA with Tukey’s posttest to assess statistical significance (I and J) (****, P < 0.0001; **, P < 0.01. No statistical significance was found in panel A. The experiment was performed in triplicate.
    Htb 15 J Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1039 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/htb 15 j cells/product/ATCC
    Average 96 stars, based on 1039 article reviews
    htb 15 j cells - by Bioz Stars, 2026-03
    96/100 stars

    Images

    1) Product Images from "VAMP8 Contributes to the TRIM6-Mediated Type I Interferon Antiviral Response during West Nile Virus Infection"

    Article Title: VAMP8 Contributes to the TRIM6-Mediated Type I Interferon Antiviral Response during West Nile Virus Infection

    Journal: Journal of Virology

    doi: 10.1128/JVI.01454-19

    Depletion of VAMP8 impairs STAT1 phosphorylation downstream of IFN-I signaling but does not alter WNV replication. (A and B) wt A549 cells were treated with nontargeting control (control) or VAMP8-targeting (VAMP8) siRNAs for 24 h, followed by infection with WNV 385-99 (MOI of 0.1) for 72 h. Supernatants and lysates of infected cells were collected at 1, 6, 24, 48, and 72 h p.i. to assess viral loads by plaque assays (A) and protein expression and phosphorylation by Western blotting (B). (C and D) The bands in the Western blot were quantified by densitometry as described in the legend of Fig. 1. (E to J) wt A549 (E to I) or ATCC HTB-15 (J) cells were treated with nontargeting control (siControl) or VAMP8-targeting (siVAMP8) siRNAs for 24 h, followed by treatment with recombinant human IFN-β-1a (500 U/ml) (E, F, I, and J) or human IFN-γ (500 U/ml) (G and H). IFN treatments shown in panels E, F, I, and J were done for 16 h. Cells were lysed, and either protein (E to H) or RNA (I and J) was isolated for analysis by Western blotting or qRT-PCR, respectively. Error bars represent standard deviations. Gene expression data were analyzed using one-way ANOVA with Tukey’s posttest to assess statistical significance (I and J) (****, P < 0.0001; **, P < 0.01. No statistical significance was found in panel A. The experiment was performed in triplicate.
    Figure Legend Snippet: Depletion of VAMP8 impairs STAT1 phosphorylation downstream of IFN-I signaling but does not alter WNV replication. (A and B) wt A549 cells were treated with nontargeting control (control) or VAMP8-targeting (VAMP8) siRNAs for 24 h, followed by infection with WNV 385-99 (MOI of 0.1) for 72 h. Supernatants and lysates of infected cells were collected at 1, 6, 24, 48, and 72 h p.i. to assess viral loads by plaque assays (A) and protein expression and phosphorylation by Western blotting (B). (C and D) The bands in the Western blot were quantified by densitometry as described in the legend of Fig. 1. (E to J) wt A549 (E to I) or ATCC HTB-15 (J) cells were treated with nontargeting control (siControl) or VAMP8-targeting (siVAMP8) siRNAs for 24 h, followed by treatment with recombinant human IFN-β-1a (500 U/ml) (E, F, I, and J) or human IFN-γ (500 U/ml) (G and H). IFN treatments shown in panels E, F, I, and J were done for 16 h. Cells were lysed, and either protein (E to H) or RNA (I and J) was isolated for analysis by Western blotting or qRT-PCR, respectively. Error bars represent standard deviations. Gene expression data were analyzed using one-way ANOVA with Tukey’s posttest to assess statistical significance (I and J) (****, P < 0.0001; **, P < 0.01. No statistical significance was found in panel A. The experiment was performed in triplicate.

    Techniques Used: Infection, Expressing, Western Blot, Recombinant, Isolation, Quantitative RT-PCR



    Similar Products

    htb 15 j cells  (ATCC)
    96
    ATCC htb 15 j cells
    Depletion of VAMP8 impairs STAT1 phosphorylation downstream of IFN-I signaling but does not alter WNV replication. (A and B) wt A549 cells were treated with nontargeting control (control) or VAMP8-targeting (VAMP8) siRNAs for 24 h, followed by infection with WNV 385-99 (MOI of 0.1) for 72 h. Supernatants and lysates of infected cells were collected at 1, 6, 24, 48, and 72 h p.i. to assess viral loads by plaque assays (A) and protein expression and phosphorylation by Western blotting (B). (C and D) The bands in the Western blot were quantified by densitometry as described in the legend of Fig. 1. (E to J) wt A549 (E to I) or ATCC HTB-15 (J) cells were treated with nontargeting control (siControl) or VAMP8-targeting (siVAMP8) siRNAs for 24 h, followed by treatment with recombinant human IFN-β-1a (500 U/ml) (E, F, I, and J) or human IFN-γ (500 U/ml) (G and H). IFN treatments shown in panels E, F, I, and J were done for 16 h. Cells were lysed, and either protein (E to H) or RNA (I and J) was isolated for analysis by Western blotting or qRT-PCR, respectively. Error bars represent standard deviations. Gene expression data were analyzed using one-way ANOVA with Tukey’s posttest to assess statistical significance (I and J) (****, P < 0.0001; **, P < 0.01. No statistical significance was found in panel A. The experiment was performed in triplicate.
    Htb 15 J Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/htb 15 j cells/product/ATCC
    Average 96 stars, based on 1 article reviews
    htb 15 j cells - by Bioz Stars, 2026-03
    96/100 stars
    		  Buy from Supplier
    atcc htb 15 j cells  (ATCC)
    96
    ATCC atcc htb 15 j cells
    Depletion of VAMP8 impairs STAT1 phosphorylation downstream of IFN-I signaling but does not alter WNV replication. (A and B) wt A549 cells were treated with nontargeting control (control) or VAMP8-targeting (VAMP8) siRNAs for 24 h, followed by infection with WNV 385-99 (MOI of 0.1) for 72 h. Supernatants and lysates of infected cells were collected at 1, 6, 24, 48, and 72 h p.i. to assess viral loads by plaque assays (A) and protein expression and phosphorylation by Western blotting (B). (C and D) The bands in the Western blot were quantified by densitometry as described in the legend of Fig. 1. (E to J) wt A549 (E to I) or ATCC HTB-15 (J) cells were treated with nontargeting control (siControl) or VAMP8-targeting (siVAMP8) siRNAs for 24 h, followed by treatment with recombinant human IFN-β-1a (500 U/ml) (E, F, I, and J) or human IFN-γ (500 U/ml) (G and H). IFN treatments shown in panels E, F, I, and J were done for 16 h. Cells were lysed, and either protein (E to H) or RNA (I and J) was isolated for analysis by Western blotting or qRT-PCR, respectively. Error bars represent standard deviations. Gene expression data were analyzed using one-way ANOVA with Tukey’s posttest to assess statistical significance (I and J) (****, P < 0.0001; **, P < 0.01. No statistical significance was found in panel A. The experiment was performed in triplicate.
    Atcc Htb 15 J Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/atcc htb 15 j cells/product/ATCC
    Average 96 stars, based on 1 article reviews
    atcc htb 15 j cells - by Bioz Stars, 2026-03
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    Depletion of VAMP8 impairs STAT1 phosphorylation downstream of IFN-I signaling but does not alter WNV replication. (A and B) wt A549 cells were treated with nontargeting control (control) or VAMP8-targeting (VAMP8) siRNAs for 24 h, followed by infection with WNV 385-99 (MOI of 0.1) for 72 h. Supernatants and lysates of infected cells were collected at 1, 6, 24, 48, and 72 h p.i. to assess viral loads by plaque assays (A) and protein expression and phosphorylation by Western blotting (B). (C and D) The bands in the Western blot were quantified by densitometry as described in the legend of Fig. 1. (E to J) wt A549 (E to I) or ATCC HTB-15 (J) cells were treated with nontargeting control (siControl) or VAMP8-targeting (siVAMP8) siRNAs for 24 h, followed by treatment with recombinant human IFN-β-1a (500 U/ml) (E, F, I, and J) or human IFN-γ (500 U/ml) (G and H). IFN treatments shown in panels E, F, I, and J were done for 16 h. Cells were lysed, and either protein (E to H) or RNA (I and J) was isolated for analysis by Western blotting or qRT-PCR, respectively. Error bars represent standard deviations. Gene expression data were analyzed using one-way ANOVA with Tukey’s posttest to assess statistical significance (I and J) (****, P < 0.0001; **, P < 0.01. No statistical significance was found in panel A. The experiment was performed in triplicate.

    Journal: Journal of Virology

    Article Title: VAMP8 Contributes to the TRIM6-Mediated Type I Interferon Antiviral Response during West Nile Virus Infection

    doi: 10.1128/JVI.01454-19

    Figure Lengend Snippet: Depletion of VAMP8 impairs STAT1 phosphorylation downstream of IFN-I signaling but does not alter WNV replication. (A and B) wt A549 cells were treated with nontargeting control (control) or VAMP8-targeting (VAMP8) siRNAs for 24 h, followed by infection with WNV 385-99 (MOI of 0.1) for 72 h. Supernatants and lysates of infected cells were collected at 1, 6, 24, 48, and 72 h p.i. to assess viral loads by plaque assays (A) and protein expression and phosphorylation by Western blotting (B). (C and D) The bands in the Western blot were quantified by densitometry as described in the legend of Fig. 1. (E to J) wt A549 (E to I) or ATCC HTB-15 (J) cells were treated with nontargeting control (siControl) or VAMP8-targeting (siVAMP8) siRNAs for 24 h, followed by treatment with recombinant human IFN-β-1a (500 U/ml) (E, F, I, and J) or human IFN-γ (500 U/ml) (G and H). IFN treatments shown in panels E, F, I, and J were done for 16 h. Cells were lysed, and either protein (E to H) or RNA (I and J) was isolated for analysis by Western blotting or qRT-PCR, respectively. Error bars represent standard deviations. Gene expression data were analyzed using one-way ANOVA with Tukey’s posttest to assess statistical significance (I and J) (****, P < 0.0001; **, P < 0.01. No statistical significance was found in panel A. The experiment was performed in triplicate.

    Article Snippet: In contrast, the amount of pSTAT1 (Y701) was notably smaller in the VAMP8-kd cells, suggesting impairment in the IFN-I signaling pathway ( and ). fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window FIG 4 caption a7 Depletion of VAMP8 impairs STAT1 phosphorylation downstream of IFN-I signaling but does not alter WNV replication. (A and B) wt A549 cells were treated with nontargeting control (control) or VAMP8-targeting (VAMP8) siRNAs for 24 h, followed by infection with WNV 385-99 (MOI of 0.1) for 72 h. Supernatants and lysates of infected cells were collected at 1, 6, 24, 48, and 72 h p.i. to assess viral loads by plaque assays (A) and protein expression and phosphorylation by Western blotting (B). (C and D) The bands in the Western blot were quantified by densitometry as described in the legend of . (E to J) wt A549 (E to I) or ATCC HTB-15 (J) cells were treated with nontargeting control (siControl) or VAMP8-targeting (siVAMP8) siRNAs for 24 h, followed by treatment with recombinant human IFN-β-1a (500 U/ml) (E, F, I, and J) or human IFN-γ (500 U/ml) (G and H).

    Techniques: Infection, Expressing, Western Blot, Recombinant, Isolation, Quantitative RT-PCR